1 / 21

Extended-Release Naltrexone for Opioid Relapse Prevention in Criminal Justice Offenders

This study examines the impact of extended-release naltrexone on opioid relapse among adults involved in the US criminal justice system compared to usual care. Results show that extended-release naltrexone leads to longer time to return to opioid use, lower rate of opioid use, and higher rate of opioid-negative urine samples.

damy
Télécharger la présentation

Extended-Release Naltrexone for Opioid Relapse Prevention in Criminal Justice Offenders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June, 2016

  2. Featured Article Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. Lee JD, et al. N Engl J Med. 2016;374(13):1232–1242.

  3. Study Objectives • To examine a 24-week course of extended-release naltrexone, compared with usual care, to determine impact on return to opioid use among adults involved in the US criminal justice system. www.aodhealth.org

  4. Study Design • Randomized, open-label trial across five sites for 24 weeks. • 153 participants received extended-release naltrexone. • 155 participants received usual care to prevent return to opioid use (brief counseling and referrals for community treatment programs). www.aodhealth.org

  5. Assessing Validity of an Article about Therapy • Are the results valid? • What are the results? • How can I apply the results to patient care? www.aodhealth.org

  6. Are the Results Valid? • Were patients randomized? • Was randomization concealed? • Were patients analyzed in the groups to which they were randomized? • Were patients in the treatment and control groups similar with respect to known prognostic variables? www.aodhealth.org

  7. Are the Results Valid?(cont‘d) • Were patients aware of group allocation? • Were clinicians aware of group allocation? • Were outcome assessors aware of group allocation? • Was follow-up complete? www.aodhealth.org

  8. Were patients randomized? • Yes. • Participants were randomized in a 1:1 ratio using an urn randomization procedure. www.aodhealth.org

  9. Was randomization concealed? • Yes. • “An independent, centralized, automated telephone system made the treatment assignments.” www.aodhealth.org

  10. Were patients analyzed in the groups to which they were randomized? • Yes. www.aodhealth.org

  11. Were the patients in the treatment and control groups similar? • Yes. The characteristics of the groups at baseline were similar. www.aodhealth.org

  12. Were patients aware of group allocation? • Yes, patients were aware of group allocation based on treatment received. www.aodhealth.org

  13. Were clinicians aware of group allocation? • Yes. www.aodhealth.org

  14. Were outcome assessors aware of group allocation? • Yes. www.aodhealth.org

  15. Was follow-up complete? • 119/153 (78%) randomized to receive extended-release naltrexone completed follow up at 24 weeks • 126/155 (81%) randomized to receive 155 participants received usual care completed follow up at 24 weeks www.aodhealth.org

  16. What Are the Results? • How large was the treatment effect? • How precise was the estimate of the treatment effect? www.aodhealth.org

  17. How large and precise was the treatment effect? • During the 24-week treatment phase, participants assigned to extended-release naltrexone had a longer median time to return to ≥ 10 days of opioid use (10.5 versus 5 weeks; hazard ratio, 0.49; 95% confidence interval [CI], 0.36-0.68), a lower rate of return to such use (43% versus 64%; odds ratio, 0.43; 95% CI, 0.28-0.65), and a higher rate of opioid-negative urine samples (74% versus 56%; odds ratio, 2.30; 95% CI, 1.48-3.54), compared with usual care. • Compared with the extended-release naltrexone group, more participants in the usual care group pursued opioid agonist treatment (OAT) during the trial (11% versus 37%), primarily after returning to opioid use. • There were no overdose events reported in the extended-release naltrexone group and 7 (3 fatal) in the usual care group. www.aodhealth.org 17

  18. How Can I Apply the Results to Patient Care? • Were the study patients similar to the patients in my practice? • Were all clinically important outcomes considered? • Are the likely treatment benefits worth the potential harm and costs? www.aodhealth.org

  19. Were the study patients similar to those in my practice? • The trial was conducted across five sites in the US among people involved with the criminal justice system. • At baseline, participants preferred non-OAT approaches to treatment. • The mean age of participants was 44 years. They were: • 85% male • 77% black or Hispanic • 74% were on parole or probation • 65% had not used heroin or other opioids in the previous 30 days www.aodhealth.org

  20. Were all clinically important outcomes considered? • Yes. www.aodhealth.org

  21. Are the likely treatment benefits worth the potential harm and costs? • Costs were not reported. www.aodhealth.org

More Related